Heron Q3 net revenue $38.2M, acute care +67% YoY, FY guidance reaffirmed

HERON THERAPEUTICS, INC. /DE/

2025-Q3 EPS reported -$0.11 revenue$114,316,000

Q3 net revenue $38.2M (+16.5% YoY); YTD $114.3M.
ZYNRELEF net revenue $9.3M (+49% YoY); APONVIE $3.0M (+173% YoY).
FY 2025 guidance reaffirmed: net revenue $153-163M, adj. EBITDA $9-13M.
J-code for ZYNRELEF effective Oct 1, 2025; VAN transition complete.
Cash and investments $55.5M as of Sept 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.